• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Wall Street analysts initiate coverage of BioAge Labs

by October 21, 2024
written by October 21, 2024

Investing.com — BioAge Labs, a clinical-stage biotech company developing therapies for metabolic diseases, has attracted attention from Wall Street investment banks, with three analysts initiating coverage of the stock on Monday.

The analysts are particularly focused on BioAge’s lead asset, azelaprag, which has shown promise as an adjunct therapy to GLP-1-based weight loss treatments.

Jefferies initiated coverage with a Buy rating and a price target of $42 a share, highlighting azelaprag’s “differentiated MOA“ as an exercise mimetic for obesity.

Jefferies sees the potential for “better quality weight loss“ when used in combination with incretin therapies like tirzepatide and semaglutide. Jefferies also modeled peak adjusted revenues of approximately $1.8 billion, supported by upcoming Phase 2 data expected in 3Q25 and 2H26.

Morgan Stanley launched coverage with an Overweight rating and a $40 price target, highlighting BioAge’s collaboration with Eli Lilly (NYSE:LLY) as a significant endorsement of the company’s approach.

“We think arguably the most compelling reason to be bullish on BioAge is its partnership with Eli Lilly, which not only validates the company’s approach (Lilly is also involved in the study design and running the study) but provides potential optionality as Lilly has exclusive right of first negotiation with the Phase 2 results,“ Morgan Stanley wrote.

The bank also praised azelaprag’s ability to double the weight loss of GLP-1 therapies while improving muscle function, based on preclinical studies.

Goldman Sachs took a more cautious approach, initiating coverage without a rating but remaining optimistic about BioAge’s potential. They highlighted that azelaprag could yield a “significant dose-dependent benefit“ in weight loss, with preclinical data suggesting it delivers 2.5 times more weight loss when added to GLP-1 monotherapies.

Goldman Sachs is also watching for potential partnerships to develop oral incretin combinations, viewing this as a major growth opportunity.

All three firms noted that Phase 2 data, in combination with GLP-1 therapies, will be key milestones. Results from the STRIDES study with tirzepatide are expected in 3Q25, with further data from a semaglutide combination anticipated in 2H26.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
US Supreme Court won’t hear Michael Cohen bid to revive suit against Donald Trump
next post
Applovin, Boeing Rise Among Monday’s Morning Market Cap Stock Movers

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • China urges palatable EV trade solution from EU as France defends bloc
    • UK finance minister Reeves promises economic ‘reset’ in upcoming budget

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy